Abstract
Introduction
Dual antiplatelet therapy consists of P2Y12 receptor antagonist such as clopidogrel, prasugrel, or ticagrelor, in combination with aspirin. This therapy represents the main medical treatment in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI), and in secondary prevention of atherothrombotic events [1, 2] .
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Among them, clopidogrel used to be the most broadly prescribed P2Y12 receptor inhibitor with undisputable benefits especially in combination with aspirin. However, since 2003, studies suggested that the pharmacodynamic effect of clopidogrel considerably varies among individuals, implying that it may lead to the occurrence of ischemic or bleeding events [3, 4] . These events were once known as clopidogrel resistance, or clopidogrel non-responsiveness, and they are now identified as high on-treatment platelet reactivity (HTPR). Up to 25-50% of patients treated with clopidogrel show inadequate pharmacological response and a consequent inadequate protection from major adverse cardiac events (MACEs) [5, 6] . The meta-analysis performed by Sofi et al. [7] revealed a significant association between residual platelet reactivity under clopidogrel treatment and recurrent cardiovascular events. Thus, in order to improve the antiplatelet effect of clopidogrel, personalized antiplatelet therapy (PAPT) is increasingly more important.
In clinical practice, some laboratory tests include platelet function test (PFT) and genetic detection andare available to fulfill PAPT in a relatively objective manner. Nevertheless, the routine measurement of platelet reactivity has not been widely implemented, and lack of consensus concerning optimal method and the best cut-off value associated with clinical risk has hindered the consideration of platelet function testing in clinical guidelines. According to a systematic review performed by Winter et al. [8] , although PAPT monitored by PFT seems to be feasible, the contradictory results of smaller registry studies and larger randomized trials with regards to outcome remains uncertain. Another approach is the genotype test. As a pro-drug, clopidogrel requires enteric and hepatic transformation by the cytochrome P450 (CYP) system to exert its antiplatelet effect. CYP2C19 enzyme seems to have the most prominent role in the production of clopidogrel active metabolite, while CYP2B6, CYP1A2, CYP3A/A5, and CYP2C9 show lesser involvement [9] . According to the systematic review performed by Osnabrugge et al. [10] , at least 11 meta-analyses on the association between CYP2C19 loss-of-function alleles and clinical efficacy of clopidogrel were identified until 2014. However, the conclusions of these meta-analyses were not consistent.
Recently, many studies evaluating the risk of MACEs and bleeding events were performed among patients receiving clopidogrel carrying different CYP2C19 genotypes or presenting different HTPR status as measured by PFT, including several randomized controlled trials (RCTs), such as GRAVITAS [11] . However, the conclusions of these studies are not consistent. In this study, a metaanalysis was performed to further evaluate the benefits of PAPT in coronary artery disease (CAD) patients. Compared with previous studies, our meta-analysis included all PAPT available, not only PFTs but also genetic detection as intervention.
Methods

Trial selection and search strategy
All published RCTs enrolling CAD patients treated with PAPT according to genetic detection or PFT for at least 1 month were selected. Controlled intervention was the standard antiplatelet therapy not guided by genetic detection or PFT.
The In addition, the references of the collected studies were checked for additional analysis.
Trials belonging to the following categories were excluded: (i) non-RCTs; (ii) subjects not treated with P2Y12 receptor antagonist; (iii) treatment duration < 1 month; and (iv) trials with no mention of MACEs or bleeding events prevention. Two investigators (Y. Zhang and P. Zhang) independently selected the studies according to the following steps: (i) titles and abstracts examination to remove irrelevant reports; (ii) full text collection of potentially relevant reports; (iii) full-text reports examination for compliance of studies with eligibility criteria; and (iv) final decisions on study inclusion and data collection. Any discrepancies were resolved by consensus. If a consensus could not be reached, the senior author (Y.L. Hou) made the final decision for trial eligibility and data extraction.
A total number of 1055 relevant articles were retrieved from PubMed (561), Embase (633), and Cochrane Controlled Trials Register (854). Among them, 14 studies [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] reporting the differences in terms of MACEs and bleeding events between 9497 patients with and without the PAPT were considered eligible for our meta-analysis (4878 randomized to PAPT and 4619 to control) (Fig. 1) . The baseline characteristics of the patients and trials key features are shown in Table 1 . All the enrolled patients suffered from CAD and underwent stenting. The antiplatelet strategy in PAPT (Fig. 2) .
In order to identify the heterogeneity source in MACEs group, meta-regression and subgroup analyses were performed. The results revealed that the benefits of receiving PAPT had no clear linear relation with the follow-up period (Coef. = 0.120, Std. Err. = 0.059, p = 0.068) (Fig. 3) (Fig. 4) . Sensitivity analysis was performed through the Trim and Fill method, and no obvious difference was found after Trim and Fill processes, suggesting that the pooled estimates in each group were relatively robust ( Table 2 ). Another post-hoc sensitivity analysis was performed by omitting studies on the basis of subgroup analysis. It seems that VerifyNow assay is outlier, so all outcomes were redone without studies using VerifyNow, wherein similar results were obtained (Table 3 ). According to the funnel plot (Fig. 5 ) and Egger's regression (Table 2) 
Discussion
In recent years, the precision of medicine has been increasingly attracting attentions, PFTs and pharmacogenomics have been rapidly developing and are becoming an important approach for PAPT in reducing the risk of MACEs occurrence after stenting, especially in patients with HTPR, exactly as the present meta-analysis has discovered. According to a recent RCT, both genotyping (CYP2C19) and PFT (VerifyNew p2Y12 assay) all resulted in an improved platelet inhibition [25] .
Platelet function testing
At present, many PFT methods are available, while the cut-off values of clopidogrel low response are different due to different test methods. A study [26] ischemic stroke. After 1 year, the results showed that only LTA, VerifyNow, and Plateletworks were significantly associated with the primary end point. However, the predictive accuracy of these tests were only modest. None of the tests provided accurate prognostic information to identify low-risk patients at higher risk of bleeding following stent implantation.
The results of our meta-analysis revealed that the preventive effects of PAPT on MACEs were more evident during a short follow-up period, and the difference was statistically significant according to the subgroup analysis, specially between 1 month and 12 month subgroups (1 month: RR 0.06, 95% CI 0.01-0.29, p = 0.0006; 6 months: RR 0.44, 95% CI 0.14-1.42, p = 0.17; 12 months: RR 0.68, 95% CI 0.50-0.93, p = 0.01; heterogeneity among subgroups: Chi 2 = 8.90, p = 0.01). During antiplatelet therapy in patients after coronary stenting, the platelet function is constantly changing, suggesting that the PFT time window is potentially influencing PAPT benefits. During a short follow-up research, the proportion of this time window in follow-up period is higher, thus the benefits might be greater. However, this speculation needs more short follow-up periods or a wider PFT time window to verify.
The subgroup analysis based on PAPT strategy found that all methods could provide benefits except VerifyNow, although no statistical difference was found among all strategic results. Due to its mature detection method, VerifyNow results have high specificity and sensibility, thus the stated hypothesis was that the above non-significant results were related with the VerifyNow cut-off value. It is generally accepted that ≥ 230 U can be considered as HTPR in the VerifyNow method, but the cut-off value remains controversial. Perhaps a lower cutoff of 208 U is more suitable, as suggested in one meta-analysis [27] and ANTARCTIC study [24] .
Genetic detection
Currently, several pharmacogenetic studies have found that gene loci plurality was related to cardiovascular events, which might predict the reactivity of antiplatelet medicine [28, 29] . Polymorphisms are present in many genes including P2Y12, GP IIb/IIIa, GP Ia/IIa, GP Ib/IX/V, CYP2C19, CYP2C9, CYP3A4, CYP3A5, COX-1, COX-2 and ABCB1 [29, 30] . However, at present CYP2C19 gene polymorphism is the only one related to clopidogrel antiplatelet effect [31, 32] . The loss-of-function gene (CYP2C19*2, *3) carriers show low reaction to clopidogrel [33] , while carriers of gain-of-function gene (CYP2C19*17) tend to show higher hemorrhage risk [34] .
Clopidogrel and prasugrel are all thienopyridine prodrugs, and all need CYP450 enzyme metabolism to translate into the activated product. Clopidogrel is predominantly converted to an inactive derivative, with only a minor fraction (15%) undergoing the 2-sequential oxidation steps to generate the active metabolite [35] . CYP2C19, CYP3A4/5 and CYP1A2 are all important enzymes in this process. The metabolic efficiency of prasugrel is relatively higher, with more than 50% of the drug becoming bioactivated, and primarily mediated by CYP3A4 and CYP2B6 enzymes [36] . Currently, the effect of CYP2C19 polymorphisms on clopidogrel therapy has been extensively studied. The earliest report on the correlation between CYP2C19*2 loss-of-function gene and clopidogrel low reaction dates back to 2006 [37] . More studies performed at later dates confirmed this correlation [38] [39] [40] . CYP2C19*17 gain-of--function gene is related to a reactivity increase of clopidogrel, but recent studies found that this correlation may be due to CYP2C19*2 linkage disequilibrium [41] . However, prasugrel is not significantly influenced by gene polymorphism, although some studies suggest an association [42, 43] . Subgroup analysis of TRITON-TIMI 38 did not find significant associations between common CYP variants and active metabolite levels, platelet inhibition, or clinical CV event rates [44] .
Clopidogrel and prasugrel are both substrates of p-glucoprotein efflux pump, which is encoded by the ABCB1 gene. Nevertheless, the correlation between ABCB1 polymorphism and clopidogrel pharmacodynamics is still unclear. One research paper found that patients with ABCB1 C3435T genotype had decreased clopidogrel absorption and circulating metabolite plasma levels [45] , and in TRITON-TIMI 38 study, this gene polymorphism was significantly associated with an increased risk of CV death, MI, or stroke in patients under clopidogrel treatment [44] . However, the GIFT study revealed that ABCB1 polymorphism was not a significant factor in pharmacologic or clinical outcomes in patients treated with clopidogrel [46] . Multiple studies have investigated the influence of other gene polymorphisms, such as CYP2C9, CYP3A4, CYP3A5, P2Y12 on clopidogrel response variability, with results being mostly non-significant [36] . The GIFT study observed the correlation between 17 gene loci and platelet reactivity in more than 1,000 patients receiving standard or high-dose clopidogrel after PCI, and found that only CYP2C19*2 was associated with HTPR [46] . Ticagrelor is a new non-thienopyridine antiplatelet medicine, which in 2011 was approved for use in patients with ACS or a history of MI. Studies on ticagrelor pharmacogenetics are limited, and no significant association between its effects and certain genotypes have been found. The subgroup analysis of DISPERSE and DISPERSE-2 studies investigated the correlation between P2Y12, P2Y1, ITGB3 gene polymorphism and the effects of ticagrelor, and found no association [47] . Besides, RESPOND and ONSET/OFFSET studies found that the effect of ticagrelor is unrelated to CYP2C19 and ABCB1 gene polymorphism [48] . The data of the PLATO trial were further investigated to search for potential genetic determinants, with at least 2 genome wide association study (GWAS) failing to find any significant effect of therapy associated polymorphisms on clinical outcomes [49, 50] . 
Publication bias
The funnel plots are obviously asymmetric, which indicate a potential publication bias in this meta-analysis. And Egger's regression was performed because the interpretation of funnel plots is largely subjective. Although the absence of a significant correlation or regression cannot be taken as evidence of symmetry, it confirmed publication bias from another perspective ( Table 2 ). After that, a more interesting question would be what is its impact on these conclusions? It was identified from the results of trim and fill processes, which was performed in the sensitivity analysis. After the trim and fill adjustment, 3 imputed studies are shown as filled circles, and imputed point estimate in log units is shown as a filled diamond at 0.156 (0.085, 0.227), corresponding to a OR of 1.169 (1.089, 1.254). The adjusted point estimate suggests a lower benefit than the original analysis. Thus, the adjusted estimate is fairly close to the original, and it was thought that they have similar substantive implications.
Conclusions
In conclusion, patients undergoing coronary stenting, PAPT could reduce the risk of MACEs, ST and MI. The preventive effect on MACEs was more significant in patients with HTPR. However, there was no significant increase in CV death, bleeding events and ischemic stroke.
